A 4-year-old 4.7-kg (10.4-lb) intact female domestic short-haired cat with a history of left forelimb amputation due to periarticular histiocytic sarcoma (HS) was referred to the Oncology Unit at the University of Bologna. Seven months prior to referral, the cat had been evaluated by the referring veterinarian for a 1-month history of a Grade 3 left forelimb lameness. Initially, the cat had been treated with oral meloxicam (Metacam, Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany) at 0.05 mg/kg (0.02 mg/lb) q 24 h for 1 week with exercise restriction. Despite initial clinical improvement, lameness recurred, and a mild soft tissue swelling of the left distal radioulnar joint developed within a few weeks. Regrettably, the travel restrictions due to the Coronavirus pandemic delayed the consultation with an oncologist. The cat was re-evaluated by the referring veterinarian only 5 months after the first presentation. At that time, initial diagnostic tests included a left forelimb radiograph (latero-medial view), three-view thoracic radiographs, abdominal ultrasound, and routine blood analysis (complete blood count, serum biochemistry, and clotting profile). Forelimb radiography revealed severe permeative lysis of the carpal bones extending across the joint space to the distal radial and ulnar epiphyses and diaphyses, as well as to the first metacarpal bone. Destruction of both medullary and cortical bone was evidenced at these sites with an ill-defined transition zone, along with moderate adjacent soft tissue swelling.The rest of the diagnostic procedures were unremarkable. Due to suspected neoplastic disease, a core biopsy of the bone lesion was submitted for histopathologic evaluation. Microscopic examination